REG - Oncimmune Hldgs PLC - Investor Presentation via Investor Meet Company

Oncimmune HoldingsAnnouncement

17/05/2024 10:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240517:nRSQ9148Oa&default-theme=true

RNS Number : 9148O  Oncimmune Holdings PLC  17 May 2024

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

Investor Presentation via Investor Meet Company

 

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company
to the pharmaceutical and biotechnology industry enabling precision medicine,
is pleased to announce that Martin Gouldstone, CEO, and Martin Hudson, Finance
Director, will provide a live presentation relating to the unaudited interim
results for the six months ended 29 February 2024 ("H1 FY2024"), which are
expected to be announced on Tuesday 21 May, via Investor Meet Company on 21
May 2024, 14:00 BST.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
20 May 2024, 09:00 BST, or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet
Oncimmune via:

 

https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor
(https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor)

 

Investors who already follow Oncimmune on the Investor Meet Company platform
will automatically be invited.

 

For further information please contact:

 

 Oncimmune Holdings plc
 contact@oncimmune.com

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)
 Geoff Nash, George Dollemore, Trisyia Jamaludin (Corporate Finance)

 Nigel Birks, Ondraya Swanson (ECM)

 +44 (0) 20 7220 0500

 Zeus Capital Limited (Joint Broker)
 Dominic King, Victoria Ayton, Dan Bate

 +44 (0)20 3829 5000

 +44 (0)20 3727 1000

 

Notes to Editors

 

About Oncimmune

 

Oncimmune is a precision medicine company, specialising in analysing immune
interactions through the autoantibody profile. Taking a platform approach to
generating insights, Oncimmune is partnering with global pharmaceutical and
biotech companies, as well as contract research organisations (CROs) to
discover novel biomarkers for the development of more targeted and effective
therapies across many immune-mediated diseases. Our mission at Oncimmune is to
enable precision medicine. We help our partners to discover novel biomarkers,
drug targets and predict treatment efficacy through the application of our
platform. We are able to do this by deploying our world class scientific team
and our cutting-edge technology platform, built on years of experience in the
field. Our aim is to make this an essential tool in drug discovery and
development.

 

Oncimmune is headquartered in the UK, with its discovery and development
facility based in Dortmund, Germany and a business development team based in
the US and Europe.

 

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGCGDUCGBDGSR